MOLECULAR GENETICS OF BIPOLAR AFFECTIVE DISORDER

Lead Research Organisation: University College London
Department Name: Division of Psychiatry

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Publications

10 25 50

publication icon
Dedman A (2012) Sequencing of the ANKYRIN 3 gene (ANK3) encoding ankyrin G in bipolar disorder reveals a non-conservative amino acid change in a short isoform of ankyrin G. in American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics

 
Description MRC
Amount £902,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 03/2011 
End 03/2015
 
Description Research Grant
Amount £90,000 (GBP)
Organisation National Institutes of Health (NIH) 
Sector Public
Country United States
Start 02/2009 
End 03/2010
 
Description Stanley Medical Research Institute (SMRI), USA Grant
Amount £365,000 (GBP)
Organisation Stanley Medical Research Institute (SMRI) 
Sector Charity/Non Profit
Country Global
Start 12/2010 
End 07/2012
 
Title Bipolar case control sample 
Description DNA and Clinical Phenotype data 
Type Of Material Database/Collection of Data/Biological Samples 
Year Produced 2008 
Provided To Others? Yes  
Impact See publications listed elsewhere in this report 
 
Title Genotype and clincal data on bipolar disorder 
Description Microarray genetic data 
Type Of Material Data analysis technique 
Year Produced 2009 
Provided To Others? Yes  
Impact New understanding of biological factors in bipolar affective disorder 
 
Description Harvard UCL Lithium responsiveness collaboration 
Organisation Harvard University
Department Harvard Medical School
Country United States 
Sector Academic/University 
PI Contribution We have used genome wide association genotype data and clinical data on treatment response to the antimanic drug lithium carbonate in bipolar disorder using the University College London bipolar disorder case control sample.
Collaborator Contribution We have replicated new findings on genes predicting response to lithium treatment in bipolar disorder in samples from UCL and Harvard. We have replicated new findings on genes predicting response to lithium treatment in bipolar disorder in samples from UCL and Harvard. We have replicated new findings on genes predicting response to lithium treatment in bipolar disorder in samples from UCL and Harvard. We have replicated new findings on genes predicting response to lithium treatment in bipolar disorder in samples from UCL and Harvard.
Impact Involves multidisciplinary team of clinicians, geneticists and statistician. Perlis, R.H., Smoller, J.W., Ferreira, M.A., McQuillin, A., Bass, N., Lawrence, J., Sachs, G.S., Nimgaonkar, V., Scolnick, E.M., Gurling, H., Sklar, P. & Purcell, S. A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder, Am J Psychiatry 166, 718-25 (2009).
Start Year 2009
 
Description Harvard UCL Lithium responsiveness collaboration 
Organisation Massachusetts General Hospital
Country United States 
Sector Hospitals 
PI Contribution We have used genome wide association genotype data and clinical data on treatment response to the antimanic drug lithium carbonate in bipolar disorder using the University College London bipolar disorder case control sample.
Collaborator Contribution We have replicated new findings on genes predicting response to lithium treatment in bipolar disorder in samples from UCL and Harvard. We have replicated new findings on genes predicting response to lithium treatment in bipolar disorder in samples from UCL and Harvard. We have replicated new findings on genes predicting response to lithium treatment in bipolar disorder in samples from UCL and Harvard. We have replicated new findings on genes predicting response to lithium treatment in bipolar disorder in samples from UCL and Harvard.
Impact Involves multidisciplinary team of clinicians, geneticists and statistician. Perlis, R.H., Smoller, J.W., Ferreira, M.A., McQuillin, A., Bass, N., Lawrence, J., Sachs, G.S., Nimgaonkar, V., Scolnick, E.M., Gurling, H., Sklar, P. & Purcell, S. A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder, Am J Psychiatry 166, 718-25 (2009).
Start Year 2009
 
Description Harvard UCL Lithium responsiveness collaboration 
Organisation Massachusetts Institute of Technology
Country United States 
Sector Academic/University 
PI Contribution We have used genome wide association genotype data and clinical data on treatment response to the antimanic drug lithium carbonate in bipolar disorder using the University College London bipolar disorder case control sample.
Collaborator Contribution We have replicated new findings on genes predicting response to lithium treatment in bipolar disorder in samples from UCL and Harvard. We have replicated new findings on genes predicting response to lithium treatment in bipolar disorder in samples from UCL and Harvard. We have replicated new findings on genes predicting response to lithium treatment in bipolar disorder in samples from UCL and Harvard. We have replicated new findings on genes predicting response to lithium treatment in bipolar disorder in samples from UCL and Harvard.
Impact Involves multidisciplinary team of clinicians, geneticists and statistician. Perlis, R.H., Smoller, J.W., Ferreira, M.A., McQuillin, A., Bass, N., Lawrence, J., Sachs, G.S., Nimgaonkar, V., Scolnick, E.M., Gurling, H., Sklar, P. & Purcell, S. A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder, Am J Psychiatry 166, 718-25 (2009).
Start Year 2009
 
Description Harvard UCL Lithium responsiveness collaboration 
Organisation National Institutes of Health (NIH)
Department National Institute of Mental Health (NIMH)
Country United States 
Sector Public 
PI Contribution We have used genome wide association genotype data and clinical data on treatment response to the antimanic drug lithium carbonate in bipolar disorder using the University College London bipolar disorder case control sample.
Collaborator Contribution We have replicated new findings on genes predicting response to lithium treatment in bipolar disorder in samples from UCL and Harvard. We have replicated new findings on genes predicting response to lithium treatment in bipolar disorder in samples from UCL and Harvard. We have replicated new findings on genes predicting response to lithium treatment in bipolar disorder in samples from UCL and Harvard. We have replicated new findings on genes predicting response to lithium treatment in bipolar disorder in samples from UCL and Harvard.
Impact Involves multidisciplinary team of clinicians, geneticists and statistician. Perlis, R.H., Smoller, J.W., Ferreira, M.A., McQuillin, A., Bass, N., Lawrence, J., Sachs, G.S., Nimgaonkar, V., Scolnick, E.M., Gurling, H., Sklar, P. & Purcell, S. A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder, Am J Psychiatry 166, 718-25 (2009).
Start Year 2009
 
Description Psychiatric Genome Wide Association Study Consortium (PGC) 
Organisation Harvard University
Country United States 
Sector Academic/University 
PI Contribution We have contributed DNA from a sub sample of bipolar cases and controls. We have had shared responsibilities for management of the consortium and data analysis of a very large genetic case control sample.
Collaborator Contribution Genotyping of the UCL bipolar case control sample using microarrays. NIH grant money has enabled databases to be created for the PGC collaboration.
Impact The PGC collaboration has found new genes increasing susceptibility to bipolar affective disorder and has confirmed some that had previously been identified. Genes causing early onset and severe bipolar disorder have been identified. Ferreira, M.A., O'Donovan, M.C., Meng, Y.A., Jones, I.R., Ruderfer, D.M., Jones, L., Fan, J., Kirov, G., Perlis, R.H., Green, E.K., Smoller, J.W., Grozeva, D., Stone, J., Nikolov, I., Chambert, K., Hamshere, M.L., Nimgaonkar, V.L., Moskvina, V., Thase, M.E., Caesar, S., Sachs, G.S., Franklin, J., Gordon-Smith, K., Ardlie, K.G., Gabriel, S.B., Fraser, C., Blumenstiel, B., Defelice, M., Breen, G., Gill, M., Morris, D.W., Elkin, A., Muir, W.J., McGhee, K.A., Williamson, R., MacIntyre, D.J., MacLean, A.W., St, C.D., Robinson, M., Van Beck, M., Pereira, A.C., Kandaswamy, R., McQuillin, A., Collier, D.A., Bass, N.J., Young, A.H., Lawrence, J., Ferrier, I.N., Anjorin, A., Farmer, A., Curtis, D., Scolnick, E.M., McGuffin, P., Daly, M.J., Corvin, A.P., Holmans, P.A., Blackwood, D.H., Gurling, H.M., Owen, M.J., Purcell, S.M., Sklar, P. & Craddock, N. Nat Genet 40, 1056-8 (2008).
Start Year 2009
 
Title NK1R (TACR1) gene in bipolar affective disorder and ADHD 
Description New genetic effect in ADHD and bipolar disorder as diagnostic test and new treatment approach to these disorders 
IP Reference WO2009130465 
Protection Patent granted
Year Protection Granted 2009
Licensed Yes
Impact New drug synthesised by MRC drug development unit at NIMR Mill Hill
 
Title TACR1 agonist 
Description Genetic findings in ADHD and Bipolar disorder supported further development of a drug targeting the NK1R receptor 
Type Therapeutic Intervention - Drug
Current Stage Of Development Refinement. Non-clinical
Year Development Stage Completed 2010
Development Status Under active development/distribution
Impact No direct impacts 
 
Description Press releases 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? Yes
Primary Audience Public/other audiences
Results and Impact Press releases to accompany two publications in Nature and Nature Genetics

Widespread press coverage internationally
Year(s) Of Engagement Activity 2008,2009